1. Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.
- Author
-
Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, Markx S, Lieberman JA, and Javitch JA
- Subjects
- Animals, Dopamine D2 Receptor Antagonists, Drug Design, Humans, Schizophrenia genetics, Schizophrenia physiopathology, Signal Transduction drug effects, Antipsychotic Agents pharmacology, Drug Delivery Systems, Schizophrenia drug therapy
- Abstract
Dopamine D(2) receptor antagonism is a unifying property of all antipsychotic drugs in use for schizophrenia. While often effective at ameliorating psychosis, these drugs are largely ineffective at treating negative and cognitive symptoms. Increasing attention is being focused on the complex genetics of the illness and the signaling pathways implicated in its pathophysiology. We review targeted approaches for pharmacotherapy involving the glutamatergic, GABAergic and cholinergic pathways. We also describe several of the major genetic findings that identify signaling pathways representing potential targets for novel pharmacological intervention. These include genes in the 22q11 locus, DISC1, Neuregulin 1/ErbB4, and components of the Akt/GSK-3 pathway., (2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF